EMA has decided to grant  Orphan Drug Designation (ODD) for OXC-201 for idiopathic pulmonary fibrosis (IPF).

The US FDA has proposed reclassifying blue light cystoscopy (BLC) systems used with Photocure’s imaging agent Cysview for bladder cancer detection from Class III to Class II, a move the Norwegian medtech company says will support wider adoption of the technology in US hospitals.

The European Commission has granted orphan drug designation to Lundbeck’s investigational anti-ACTH monoclonal antibody asedebart for the treatment of endogenous Cushing’s syndrome.

Episurf Medical has concluded the strategic review of its medtech operations and will now pursue an orderly wind-down of that business, completing its transformation into a pure-play Nordic property company.

Finnish medtech company Nexstim has received an order for its latest-generation NBS 6 navigated brain stimulation system from an existing hospital customer in Europe, as the customer upgrades from an earlier-generation platform.

Finnish ophthalmic device maker Revenio’s iCare DRSplus fundus camera is now part of the first FDA-cleared AI-based diabetic retinopathy screening solution to reach the US market, through a partnership with health-tech company iHealthScreen.

Elicera Therapeutics has received a Notice of Allowance from the USPTO (United States Patent and Trademark Office) regarding its patent application for the CAR T-cell candidate ELC-401.

Lytix Biopharma is joining a new investigator-initiated Phase II study, ALETTA, that will test its lead candidate ruxotemitide in combination with ipilimumab and nivolumab in patients with early-stage, resectable melanoma – a second major checkpoint-inhibitor combination alongside the company’s existing pembrolizumab work.

Norwegian biotech Circio Holding has entered a research collaboration with US-based Full Circles Therapeutics to combine their respective circular nucleic acid platforms, aiming to build non-viral, re-dosable in vivo cell therapies as an alternative to conventional approaches like CAR-T.

Researchers at the University of Turku, working with France’s Gustave Roussy Institute, have identified a molecular mechanism that lets an aggressive subtype of colorectal cancer shield itself from chemotherapy and spread through the abdominal cavity – and shown that antibodies already used against other cancers can disrupt the process.

The Lundbeck Foundation has awarded DKK 78 million to a pan-Nordic centre that will focus on research into the glymphatic system.

From August 18-24, 2026, patients, physicians, caregivers, and supporters from around the world will embark on a six-day cycling expedition across Iceland with the purpose of accelerating research into multiple myeloma.